In the GEOMETRY mono-1 trial, Wolf et al. [80] conducted a multiple-cohort, phase 2 study and enrolled advanced NSCLC patients with MET Exon 14 skipping mutation or MET amplification. This evidence concerns the gene MET and non-small cell lung carcinoma.